According to the report, the size of the Europe Non-Invasive Cancer Diagnostics Market is valued at USD xx million in 2019 and expected to grow at a CAGR of xx.x%, to reach USD xx million by 2024 during the forecast period 2019-2024. The Europe Non-Invasive Cancer Diagnostics market is developing at an exceptionally quick pace.
A medical procedure is referred to as non- invasive when there is a slight incision in the body in diagnosis. There are various non- invasive diagnostics methods which range from simple observation to specialized surgery.
The significant drivers are increasing the incidence of cancer due to aging, and increasing awareness about an early cancer diagnosis. Advancements in cancer detection techniques are also expected to drive the market over the forecast period. However, the high cost of treatment is a major restraint limiting this industry.
Europe Non-Invasive Cancer Diagnostics Market has been segmented and sub-segmented into the following categories
On the basis of region, Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period.
Prominent Companies leading the Europe Non-Invasive Cancer Diagnostics Market Profiled in the Report are Precision Therapeutics, Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc., Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics Incorporated Cancer Genetics Inc., Digene Corporation and Gen-Probe Incorporated.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Techniques
5.1.1 Introduction
5.1.2 Clinical Chemistry
5.1.3 Immunochemistry/Immunoassay
5.1.4 Molecular Diagnostics
5.1.5 Other Clinical Instruments
5.1.6 Y-o-Y Growth Analysis, By Techniques
5.1.7 Market Attractiveness Analysis, By Techniques
5.1.8 Market Share Analysis, By Techniques
5.2 Type
5.2.1 Introduction
5.2.2 Breast Cancer
5.2.3 Blood cancer
5.2.4 Lung Cancer
5.2.5 Solid tumors
5.2.6 Others
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Techniques
6.1.3.3 By Type
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Techniques
6.1.4.3 By Type
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Techniques
6.1.5.3 By Type
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 AVIVA Biosciences Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Affymetrix Inc.
8.3 A&G Pharmaceutical
8.4 BIOVIEW Inc.
8.5 Digene Corporation
8.6 Gen-Probe Incorporated
8.7 Laboratory Corporation of America Holdings (LabCorp)
8.8 Precision Therapeutics
8.9 Quest Diagnostics Incorporated
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
